Pierre-Yves Genson1, Eric Mourey1, Morgan Moulin1, Sylvain Favelier1, Lucy Di Marco1, Olivier Chevallier1, Jean-Pierre Cercueil1, Denis Krausé1, Luc Cormier1, Romaric Loffroy1. 1. 1 Department of Vascular, Oncologic and Interventional Radiology, 2 Department of Urology and Andrology, François-Mitterrand Teaching Hospital, University of Dijon School of Medicine, 21079 Dijon Cedex, France ; 3 Department of Radiology and Radiological Science, Medical University of South Carolina, MSC 323 Charleston, USA ; 4 LE2I UMR CNRS 6306, Arts et Métiers, University of Bourgogne Franche-Comté, Dijon, France.
Abstract
BACKGROUND: The purpose is to assess the short- and mid-term outcomes of microwave ablation (MWA) of small renal tumours in selected patients. METHODS: From August 2012 to February 2015, 29 renal tumours in 23 patients (17 male, 6 female, mean age 75 years) were treated by percutaneous MWA under imaging guidance. The tumours were 1-4.7 cm in diameter (mean size, 2.7 cm). Therapeutic effects were assessed at follow-up with magnetic resonance imaging (MRI). All patients were followed up for 2-25 months (mean, 12.2 months) to observe the therapeutic effects and complications. Changes in renal function at day 1 after treatment were statistically analyzed using the Student paired t-test or the paired Wilcoxon test. RESULTS: Technical success was achieved in all cases. One severe bleeding complication post-procedure occurred leading to death. No other unexpected side effects were observed after the MWA procedures. Clinical effectiveness was 100%. None of the patients showed recurrence on MRI imaging follow-up. No significant changes in renal function were noted after treatment (P=0.57). CONCLUSIONS: Our preliminary study demonstrates that the use of MWA for the treatment of small renal tumours can be applied as safely and efficiently as other ablative techniques in selected patients not eligible for surgery.
BACKGROUND: The purpose is to assess the short- and mid-term outcomes of microwave ablation (MWA) of small renal tumours in selected patients. METHODS: From August 2012 to February 2015, 29 renal tumours in 23 patients (17 male, 6 female, mean age 75 years) were treated by percutaneous MWA under imaging guidance. The tumours were 1-4.7 cm in diameter (mean size, 2.7 cm). Therapeutic effects were assessed at follow-up with magnetic resonance imaging (MRI). All patients were followed up for 2-25 months (mean, 12.2 months) to observe the therapeutic effects and complications. Changes in renal function at day 1 after treatment were statistically analyzed using the Student paired t-test or the paired Wilcoxon test. RESULTS: Technical success was achieved in all cases. One severe bleeding complication post-procedure occurred leading to death. No other unexpected side effects were observed after the MWA procedures. Clinical effectiveness was 100%. None of the patients showed recurrence on MRI imaging follow-up. No significant changes in renal function were noted after treatment (P=0.57). CONCLUSIONS: Our preliminary study demonstrates that the use of MWA for the treatment of small renal tumours can be applied as safely and efficiently as other ablative techniques in selected patients not eligible for surgery.
Authors: J-J Patard; H Baumert; K Bensalah; J-C Bernhard; P Bigot; B Escudier; N Grenier; J-F Hétet; J-A Long; A Méjean; P Paparel; S Richard; N Rioux-Leclercq; P Coloby; M Soulié Journal: Prog Urol Date: 2013-11 Impact factor: 0.915
Authors: R Houston Thompson; Tom Atwell; Grant Schmit; Christine M Lohse; A Nicholas Kurup; Adam Weisbrod; Sarah P Psutka; Suzanne B Stewart; Matthew R Callstrom; John C Cheville; Stephen A Boorjian; Bradley C Leibovich Journal: Eur Urol Date: 2014-08-06 Impact factor: 20.096